GLP-1RAs linked to telogen effluvium and androgenic alopecia; risk rises with dose, duration.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for type 2 diabetes mellitus and chronic weight management, demonstrating significant efficacy. However, their widespread use has brought emerging concerns regarding dermatologic adverse effects, particularly various forms of alopecia. Current understanding lacks clarity on the prevalence, specific agents involved, and underlying mechanisms of GLP-1RA-associated hair loss, creating a critical gap for patient counseling and clinical management.

Researchers conducted a scoping review of literature concerning GLP-1RAs and alopecia. The search utilized PubMed and included articles published up to April 2026, aiming to evaluate the prevalence of GLP-1RA-associated alopecia, identify differences among specific agents, and explore proposed underlying mechanisms. This methodology allowed for a broad overview of existing evidence without synthesizing quantitative data from individual studies.

Current literature presents conflicting evidence regarding the effects of GLP-1RAs on hair loss. Available data suggest an association between GLP-1RAs and both telogen effluvium and androgenic alopecia. The risk of hair loss potentially increases with longer duration of use, greater weight loss, and higher doses, particularly observed with tirzepatide and semaglutide. Proposed mechanisms include weight loss-related physiological changes, alterations in dermal white adipose tissue, and various hormonal influences, though their relative contributions remain unclear. > Conversely, a smaller body of literature suggests improvement in inflammatory alopecia with GLP-1RA use, especially among patients with underlying metabolic dysfunction. This highlights a complex, potentially dual role depending on the type of alopecia.